Registro sencillo

dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.contributor.authorAyala, Unai
dc.contributor.authorBarrenechea, Maitane
dc.contributor.otherMurueta-Goyena, Ane
dc.contributor.otherPino, Rocío Del
dc.contributor.otherGaldós, Marta
dc.contributor.otherArana, Begoña
dc.contributor.otherCarmona-Abellán, Mar
dc.contributor.otherFernández-Valle, Tamara
dc.contributor.otherTijero, Beatriz
dc.contributor.otherLucas-Jiménez, Olaia
dc.contributor.otherOjeda, Natalia
dc.contributor.otherIbarretxe-Bilbao, Naroa
dc.contributor.otherPeña, Javier
dc.contributor.otherCortes, Jesus
dc.contributor.otherGómez-Esteban, Juan Carlos
dc.contributor.otherGabilondo Cuellar, Iñigo
dc.date.accessioned2020-11-02T17:03:08Z
dc.date.available2020-11-02T17:03:08Z
dc.date.issued2021
dc.identifier.issn1531-8249en
dc.identifier.otherhttps://katalogoa.mondragon.edu/janium-bin/janium_login_opac.pl?find&ficha_no=161555en
dc.identifier.urihttps://hdl.handle.net/20.500.11984/1880
dc.description.abstractObjective: To analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson’s disease (iPD). Methods: Patients with Lewy body diseases (LBDs) were enrolled and prospectively evaluated at 3 years, including patients with iPD (n=42), dementia with Lewy bodies (DLB, n=4), E46K-SNCA mutation carriers (n=4) and controls (n=17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment (MoCA), and Unified Parkinson’s Disease Rating Scale (UPDRS) score was obtained in patients. Macular ganglion-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thickness and the risk of subsequent cognitive and motor worsening, using clinically meaningful cut-offs. Results: GCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63 µm in iPD patients and 0.23 µm in controls (p<0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (RR 3.49, 95% CI 1.10 – 11.1, p=0.03 and RR 3.28, 95% CI 1.03 – 10.45, p=0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Interpretation: Our results provide evidence of the potential use of OCT-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD.es
dc.description.sponsorshipMichael J. Fox Foundationes
dc.description.sponsorshipGobierno de Españaes
dc.description.sponsorshipGobierno de Españaes
dc.description.sponsorshipGobierno de Españaes
dc.description.sponsorshipGobierno Vascoes
dc.description.sponsorshipGobierno Vascoes
dc.language.isoengen
dc.publisherWileyen
dc.rights© The Authorsen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectneurodegenerationen
dc.subjectvisual dysfunctionen
dc.subjectoptical coherence tomographyen
dc.titleRetinal thickness predicts the risk of cognitive decline in Parkinson's diseaseen
dcterms.accessRightshttp://purl.org/coar/access_right/c_abf2en
dcterms.sourceAnnals of Neurologyen
local.contributor.groupTeoría de la señal y comunicacioneses
local.description.peerreviewedtrueen
local.identifier.doihttps://doi.org/10.1002/ana.25944en
local.relation.projectIDRRIA 2014 (Rapid Response Innovation Awards) Program (Grant ID: 10189)en
local.relation.projectIDGE/Instituto de Salud Carlos III/PI14-00679/ES/Estudio por neuroimagen de los portadores de la mutación E46K del gen de la alfa sinucleína como modelo de enfermedad por cuerpos de Lewy idiopática/en
local.relation.projectIDGE/Instituto de Salud Carlos III/PI16-00005/ES/Identificación de biomarcadores de la retina y la vía visual en formas genéticas de enfermedad de Parkinson como un modelo para enfermedad de Parkinson idiopática/en
local.relation.projectIDGE/Instituto de Salud Carlos III. Contratos Juan Rodés/JR15-00008///en
local.relation.projectIDGV/Ayudas a proyectos de investigación y desarrollo en salud 2016/2016111009/CAPV/Identificación de biomarcadores de la retina y la vía visual en formas genéticas de enfermedad de Parkinson como un modelo para enfermedad de Parkinson idiopática/en
local.relation.projectIDGV/Ayudas a proyectos de investigación y desarrollo en salud 2020/2020333033/CAPV/Aplicación clínica de la inteligencia artificial sobre imágenes de OCT de retina para la clasificación precoz y monitorización de pacientes con enfermedad de Parkinson/en
local.rights.publicationfeeAPCen
local.rights.publicationfeeamount2500 EURen
local.contributor.otherinstitutionhttps://ror.org/0061s4v88es
local.contributor.otherinstitutionhttps://ror.org/000xsnr85es
local.contributor.otherinstitutionhttps://ror.org/029gnnp81es
local.contributor.otherinstitutionhttps://ror.org/03nzegx43es
local.contributor.otherinstitutionhttps://ror.org/00ne6sr39es
local.contributor.otherinstitutionhttps://ror.org/01cc3fy72es
local.source.detailsFirst published: 24 October 2020en
oaire.format.mimetypeapplication/pdf
oaire.file$DSPACE\assetstore
oaire.resourceTypehttp://purl.org/coar/resource_type/c_6501en
oaire.versionhttp://purl.org/coar/version/c_ab4af688f83e57aaen


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(es)

Registro sencillo

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International